BioToxTech Co

BioToxTech Co Buyback Yield

The Buyback Yield of BioToxTech Co (086040.KQ) as of Oct 21, 2026 is 2.05 %. In the previous year, Buyback Yield was 2.05 % — a change of 0.06% (higher).

Buyback Yield

2.05 %

YoY

0.06%

Last updated:

Buyback Yield of BioToxTech Co is 2025 2.05 % . Buyback Yield of BioToxTech Co was 2024 2.05 % . It decreases by 0.06% higher compared to the previous year.

The BioToxTech Co Buyback Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Buyback Yield
Date
Buyback Yield
Jan 1, 2018
0.68 KRW
Jan 1, 2019
0.32 KRW
Jan 1, 2020
0.51 KRW
Jan 1, 2021
0.81 KRW
Jan 1, 2022
0.00 KRW
Jan 1, 2023
0.00 KRW
Jan 1, 2024
2.05 KRW
Jan 1, 2025
2.05 KRW
The BioToxTech Co Buyback Yield history
YEARBuyback YieldYoY
2.05 %+0.06%
2.05 %—
0.00—
0.00-100.00%
0.81 %+56.76%
0.51 %+62.50%
0.32 %-53.74%
0.68 %+11.25%
0.62 %-44.20%
1.10 %-35.25%
1.70 %-87.70%
13.84 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Buyback Yield of BioToxTech Co is 2.05 % in 2025.

Buyback Yield of BioToxTech Co changed from 2.05 % to 2.05 %, representing a 0.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Buyback Yield BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

Buyback yield measures the percentage of market cap returned to shareholders through share repurchases. It complements dividend yield in assessing total shareholder returns.

To evaluate Buyback Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Buyback Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Buyback Yield's BioToxTech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — BioToxTech Co

All Key Metrics — BioToxTech Co